Global Cell and Gene Therapy CDMO Market Outlook to 2032

Executive Summary

The cell and gene therapy CDMO market is moving from clinical-stage outsourced manufacturing toward integrated commercial-scale CDMO partnerships. The category grows from US$7 billion in 2024 to US$50 billion by 2032 at 28% CAGR.

Three forces drive the trajectory. The CGT approval cohort reached operational scale: FDA approved 8 novel CGTs in 2024 and 6 new indications, bringing cumulative US approvals over 30; pipeline includes more than 2,500 active CGT INDs (approximately 1,300 gene-therapy-specific) with approximately 35 Phase 3 candidates globally; industry experts anticipate 30-50 additional approvals by 2030. Novo Holdings completed its US$16.5 billion acquisition of Catalent on December 18, 2024, described in industry coverage as "the biggest transaction of cell and gene capacity ever," with stated intent to double Catalent's size over five years. And the BIOSECURE Act (reintroduced September 2025 with 2032 decoupling deadline targeting WuXi AppTec, WuXi Biologics, BGI Group, MGI, and Complete Genomics) is reshaping CDMO supplier selection across US biotech, with WuXi Advanced Therapies experiencing 17% revenue decline through Q3 2024.

Market Overview

The CGT CDMO scope captures contract development and manufacturing services across six service lines: process development, GMP manufacturing (autologous CAR-T, allogeneic, viral vector AAV and lentivirus, gene-editing payloads, mRNA/LNP), fill-finish, quality control and release testing, logistics and cold-chain delivery (cryogenic vein-to-vein), and commercial-scale supply agreements. The category is distinct from sponsor in-house manufacturing (Gilead Kite, BMS, Novartis, Vertex's planned T1D facility with Lonza) although the same scaled CDMO operators compete to manufacture for sponsors when capacity bottlenecks force outsourcing.

The category sits at the intersection of three forces. Pharmaceutical-manufacturing capacity cycle (CGTs are the highest-margin and highest-complexity subsegment of biotech). US-China decoupling dynamic (BIOSECURE Act 2032 deadline if enacted forces approximately US$10-15 billion of supplier-shift capex through 2030). And cost-of-CGT-as-political-issue: list prices range from US$0.5 million (Casgevy, Lyfgenia) to US$3.5 million (Hemgenix), driving Medicare and commercial-payer pressure on outcomes-based pricing.

Geopolitically, North America anchors 41% of CDMO market (Catalent post-Novo, Thermo Fisher Patheon, Lonza Houston, Charles River, Resilience). Europe holds 28% (Lonza Switzerland, Catalent EU, AGC Biologics, Oxford Biomedica, Fujifilm UK). China at 11% is structurally vulnerable to BIOSECURE, could compress to 5-6% by 2032 with Indian, Korean, EU specialists capturing the substitution flow.

Market Size and Growth Outlook

The 2024-28 phase compounds at 33-36% as the FDA approval cohort reaches operational scale, Novo Holdings drives Catalent expansion at scale, BIOSECURE-driven supplier-shift accelerates substitution capex at non-Chinese CDMOs, and Gilead Kite, BMS, and Novartis quadruple CAR-T capacity. From 2030 onward growth moderates as the commercial-stage migration completes; commercial-stage CDMO revenue accounts for approximately 65% of category by 2032 versus 25% in 2024.

Market Segmentation

By Therapy Modality

Autologous CAR-T leads at 32% but is operationally complex (vein-to-vein turnaround, patient-specific manufacturing, cryogenic logistics). The fastest-growing modality is gene-edited (CRISPR, base-editing) at 11% expanding to 22% by 2032, driven by Casgevy commercial ramp and the broader CRISPR/Verve/Beam pivotal-trial cohort.

By Buyer Cohort

Big pharma at 38% is the largest cohort and growing modestly faster as sponsor in-house capacity reaches saturation. Mid-cap biotech at 30% is the most strategically important because the highest-quality CGT pipeline assets (Vertex CASGEVY, Sarepta Elevidys, BioMarin Roctavian) sit here. Emerging biotech at 22% is highest-volume but lowest revenue-per-account.

By Region

North America at 41% is anchored by Catalent post-Novo, Thermo Fisher Patheon, Lonza Houston. India at 4% is the fastest-growing region (38% CAGR through 2032) on BIOSECURE-driven substitution; expected to reach 9% by 2032 as Biocon, Syngene, Lonza-Bharat scale.

Trends and Developments

Novo Holdings-Catalent integration

Novo Holdings completed its US$16.5 billion all-cash acquisition of Catalent on December 18, 2024. Catalent has more than 50 sites including production facilities for cell and gene therapies. Novo Nordisk separately acquired three fill-finish sites (Anagni Italy, Bloomington Indiana, Brussels Belgium) post-close. Novo Holdings has stated intention to double Catalent's size over five years. Industry concerns about disruption to existing partnerships with Novartis, Sarepta, and Eli Lilly are unresolved as of Q1 2026; Catalent moved to wind down EU cell therapy operations as part of strategic-review consolidation.

BIOSECURE-driven supplier-shift

The BIOSECURE Act (US H.R. 8333) targeting WuXi AppTec, WuXi Biologics, BGI Group, MGI, and Complete Genomics did not pass in 2024 but was reintroduced September 2025 with a 2032 decoupling deadline. WuXi Advanced Therapies experienced a 17% revenue decline through Q3 2024 attributed to the proposed legislation. A May 2024 BIO survey found that 79% of US biotechs surveyed contracted with at least one Chinese firm. Multi-year supplier-shift capex of approximately US$10-15 billion through 2030 across US biotech.

CAR-T capacity quadrupling

Gilead Kite is quadrupling CAR-T capacity worldwide by 2026 (from approximately 10,000 therapies/year to over 24,000/year), anchored by US$500 million February 2025 investment in a new manufacturing facility. Bristol Myers Squibb expanded its Cellares partnership across US, EU, and Japan and piloting automated closed systems. Novartis benefits from June 2025 FDA REMS removal which materially reduces site friction for Kymriah deployment.

Other relevant developments include Lonza-Vertex commercial CGT supply partnerships (CASGEVY and dedicated T1D facility), Indian CDMO entry as the leading BIOSECURE substitution beneficiary (Biocon, Syngene, Lonza-Bharat), process-development automation at Cellares and Resilience reducing labour hours per patient by 40-60%, and the Amedisys-Contessa GUIDE Model dementia integration (August 2024). The pipeline pull-through is further compounded by AI-discovered biologics candidates advancing into clinical phase, which will require commercial CDMO capacity at the back end of the discovery cycle.

Competitive Landscape

The category is moderately concentrated: top-3 (Catalent post-Novo, Lonza, Thermo Fisher Patheon) collectively control 42% of CGT CDMO revenue; top-5 (adding WuXi, Samsung) 55%. Catalent is the largest gene therapy CDMO globally with commercial CGT experience. Lonza is the most strategically defensible second position via the Vertex CASGEVY long-term commercial supply agreement and Vertex T1D dedicated facility partnership. WuXi Advanced Therapies faces highest existential risk from BIOSECURE. Samsung Biologics is the highest-quality Asian entrant building CGT capacity from biologics-manufacturing dominance.

Key Policies and Regulatory Environment

BIOSECURE Act (US H.R. 8333), reintroduced September 2025

The BIOSECURE Act prevents federally funded US pharmaceutical companies from working with named Chinese services firms: WuXi AppTec, WuXi Biologics (added May 2024), BGI Group, MGI, Complete Genomics. Did not pass in 2024 but was reintroduced September 2025 with a 2032 decoupling deadline. WuXi Advanced Therapies experienced a 17% revenue decline through Q3 2024. May 2024 BIO survey found 79% of 124 surveyed US biotechs contracted with at least one Chinese firm. If enacted, forces approximately US$10-15 billion of supplier-shift capex through 2030.

FDA Cellular and Gene Therapy regulatory framework

The FDA's Office of Therapeutic Products (within CBER) regulates CGT products. As of early 2025, over 30 cell and gene therapies have FDA approval; the office processes approximately 2,500 active CGT INDs (approximately 1,300 gene-therapy-specific). The FDA's National Priority Voucher program (used for Otarmeni 2025 approval) accelerates review for high-priority indications. The FDA's June 2025 removal of REMS requirements for select CAR-T products materially reduces commercial-deployment friction.

Other relevant frameworks include EMA Advanced Therapy Medicinal Products (ATMP) framework, China NMPA Innovative Drug pathway, and the EU AI Act high-risk classification for CGT manufacturing AI/ML applications (full enforcement August 2026). No formal CHIPS-Act-equivalent industrial policy for CGT manufacturing exists in the US as of Q1 2026, though discussion of BARDA-led federal funding has surfaced.

Future Outlook

The CGT CDMO market in 2032 reaches approximately US$50 billion. Commercial-stage CDMO accounts for 65% of category value (US$33 billion, up from US$1.7 billion in 2024). Clinical-stage 30%. The structural shift through 2032 is from "CDMO-as-clinical-development-partner" to "CDMO-as-integrated-commercial-supply-chain-operator."

The competitive landscape consolidates further. Top-5 operators collectively control 62% of category value by 2032 (up from 55% in 2024). The geographic mix shifts: China contracts from 11% to 5-6% on BIOSECURE decoupling; India expands from 4% to 9% on substitution capture; Korean Samsung Biologics expands from 5% to 8%.

The biggest risk is a cluster of late-stage CGT clinical failures and slower-than-expected post-approval commercial ramp at multiple commercial-stage products. Cautionary cases: bluebird bio go-private 2025, Sarepta Elevidys safety review questions, Catalent EU cell therapy hub wind-down. If approval volume under-delivers (under 20 additional approvals by 2030 versus anticipated 30-50), back-half forecast (2029-32) compresses by 25-35%.